In the current study, we have investigated the sensitivity of poor risk AML – a sub-classification with few treatment options – to protein phosphorylation and degradation inhibitors to reveal CKS1-dependent vulnerabilities. The gene discussed is CKS1B; the disease is acute myeloid leukemia.